Filing Flows › Bristol Myers Squibb (BMY) › Capital expenditures
Bristol Myers Squibb (BMY) capital expenditures by quarter
Bristol Myers Squibb's capital expenditures were $344M in Q3 2026 (third quarter 2026), +13% from Q2 2026. Over the last 7 quarters it ranged from $260M (Q1 2025) to $370M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $344M | +13% | +7% |
| Q2 2026 | $305M | -12% | -16% |
| Q1 2026 | $347M | -6% | +33% |
| Q4 2025 | $370M | +16% | — |
| Q3 2025 | $320M | -11% | — |
| Q2 2025 | $361M | +39% | — |
| Q1 2025 | $260M | — | — |
Q3 2026 at a glance
Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
Questions
What is Bristol Myers Squibb's capital expenditures?
Bristol Myers Squibb's capital expenditures were $344M in Q3 2026 (third quarter 2026), +13% from Q2 2026.
How has Bristol Myers Squibb's capital expenditures changed?
Over the last 7 quarters it ranged from $260M (Q1 2025) to $370M (Q4 2025).